{"id":"NCT00390910","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","officialTitle":"Study to Assess the Safety and Immunogenicity of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine When Co-administered With DTPa-HBV-IPV/Hib (Infanrix-Hexa) Vaccine in Preterm Infants as a 3-dose Primary Immunization Course During the First 6 Months of Life.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10-01","primaryCompletion":"2007-07-02","completion":"2008-05-02","firstPosted":"2006-10-23","resultsPosted":"2018-12-17","lastUpdate":"2018-12-17"},"enrollment":286,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix hexa","otherNames":["DTPa-HBV-IPV/Hib"]}],"arms":[{"label":"Synflorix™ + Infanrix™ hexa Group I","type":"EXPERIMENTAL"},{"label":"Synflorix™ + Infanrix™ hexa Group II","type":"EXPERIMENTAL"},{"label":"Synflorix™ + Infanrix™ hexa Group III","type":"EXPERIMENTAL"}],"summary":"This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.\n\nThis protocol posting deals with objectives \\& outcome measures of the primary study. The objectives \\& outcome measures of the Booster study are presented in a separate protocol posting (NCT number = 00609492)","primaryOutcome":{"measure":"Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off","timeFrame":"Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)","effectByArm":[{"arm":"Synflorix™ + Infanrix™ Hexa Group III","deltaMin":5,"sd":null},{"arm":"Pooled Group I + II","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"8 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":8,"countries":["Greece","Spain"]},"refs":{"pmids":["21727108"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":50},"commonTop":["Erythema","Irritability","Swelling","Pain","Pyrexia"]}}